

June 8, 2018

Q4FY18 Result Update

Ahluwalia Contracts (India) Ltd

Order execution ramp up – key trigger

Accumulate

Ahluwalia Contracts (India) Ltd (ACIL), for Q4FY18, reported mixed numbers. Revenue declined by 5% YoY to ₹447 crore, mainly due to slow execution and GST impact. EBITDA grew ~25% to ₹53 crore. Lower raw material cost and construction expenses led to EBITDA margin expansion of 286bps to 12%. Net profit grew 54% to ₹31 crore, on the back of lower interest cost. As of Mar'18, ACIL has reduced debt to ₹30 crore (vs ₹90 crore in Mar'17). ACIL has declared a dividend of ₹0.3/share, for the first time in the last 6 years.

Management Guidance: For FY19 and FY20, the management has guided for revenue growth of 20% each. Order inflows of ₹2,000-2,200 crore are expected in FY19, with EBITDA margins of 13-14% and working capital improvement of 3-4 days.

Recommendation: Post our Q3FY18 result update (8 Mar'18 @ ₹371, Rating: Accumulate), in-line with our expectation the stock price of ACIL touched its 52 week high of ₹445 (on 8 May'18), surpassing our then target price of ₹421. Given the current market volatility, the stock price of ACIL has corrected to ₹355, thus trading at 13.6x P/E on FY20E basis. The company continues to bid cautiously so as to safeguard its EBITDA margins, which can be attributed to the 10% decline in order inflows in FY18 to ₹1,300 crore. Given the government's focus on buildings, healthy bid pipeline and opportunities in the higher ticket size orders (₹500 crore+), we anticipate ACIL to be a beneficiary of the same. We maintain our Accumulate rating and value the company at 16x FY20E EPS giving a target price of ₹418.

Q4FY18 Result Summary

Y/E Mar (₹ Cr.)	Q4FY18	Q4FY17	YoY (%)	Q3FY18	QoQ (%)
Revenue	447	472	(5.3)	361	23.7
EBITDA	53	43	24.5	62	(14.5)
Margin (%)	12.0	9.1	286bps	17.3	-535bps
PAT	31	20	54.0	29	6.3
EPS (₹)	4.63	3.00		4.35	

Source: Company, Centrum Wealth Research

Order inflows gaining traction: Given the increasing competitive intensity, ACIL adopted a cautious bidding approach which resulted in order inflows declining by 10% YoY to ₹1,300 crore in FY18. Order book stood at ₹3,700 crore as of Mar'18. Post securing new orders worth ₹1,600 crore during the quarter, the current order book is ~₹4,700 crore (2.8x FY18 revenue), thus providing revenue visibility. ACIL's bid pipeline stands at ₹3,000 crore, which includes projects related to hospitals, airports and institution. Given the company's approach and order profile we expect the company to maintain margins of 13%+ in FY19E/20E.

Good balance sheet position: ACIL's debt as of Mar'18 stands at ₹29 crore (vs ₹61 crore in Dec'17 and ₹90 crore in Mar'17). We anticipate ACIL to be a debt free company by FY20E. We believe reduction in debt led to saving in finance cost resulting in better profitability. In addition, better order execution could aid in generating cash flows, which could help in improving working capital cycle.

Risk factors: 1) Slower than expected order execution, could impact revenue growth, 2) Increase in sub-contracting expenses to hurt margins, 3) Delay in payments leading to higher working capital requirement.

Financial Summary

Y/E Mar (₹ Cr.)	Revenue	YoY (%)	EBITDA	EBITDA (%)	NPAT	YoY (%)	EPS (₹)	P/E (x)	EV/EBITDA (x)	RoE (%)
FY16A	1,250	17.9	161	12.9	84	31.8	12.60	28.1	15.0	22.2
FY17A	1,427	14.2	173	12.1	86	1.9	12.84	27.6	13.5	18.5
FY18P	1,647	15.4	219	13.3	115	34.2	17.23	20.6	10.4	20.4
FY19E	1,921	16.7	257	13.4	152	31.3	22.62	15.7	8.6	22.0
FY20E	2,152	12.0	290	13.5	175	15.5	26.11	13.6	7.0	20.9

Source: Company, Centrum Wealth Research, P = Provisional

Key Data

Current Market Price (₹)	355
Target Price (₹)	418
Potential upside	17.9%
Sector Relative to Market	In-line
Stock Relative to Sector	In-line

Stock Information


BSE Code	532811
NSE Code	AHLUCONT
Face Value (₹/Share)	2.0
No. of shares (Cr.)	6.7
Market Cap (₹ Cr.)	2,375
Free float (₹ Cr.)	998
52 Week H / L (₹)	445/236
Avg. Daily turnover (12M, ₹ Cr.)	1.7

Shareholding Pattern (%)

	Mar-18	Mar-17
Promoters#	58.0	59.6
Mutual Funds	15.3	14.6
FPIs	20.3	19.4
Others including Public	6.4	6.4

#Promoter holding diluted post sale of shares by promoter member in Apr'17.

1 year Indexed Price Performance




Price Performance (%)

	1M	3M	6M	1YR
ACIL	(16.6)	(4.3)	(0.7)	6.4
S&P BSE Small Cap	(7.2)	(2.8)	(6.9)	8.8

Source: Bloomberg, Centrum Wealth Research

Mrinalini Chetty, Research Analyst

Exhibit 1: Order Book break-up

Source: Company, Centrum Wealth Research

Q4FY18 Concall Highlights

- With the recent addition of ₹1,600 crore worth of orders, the share of government orders has increased to ~75%. Going forward, the company is looking at an equal distribution of order book between public and private sector.
- Of the current order bid pipeline of ₹3,000 crore, private sector constitutes 20%. Opportunity in the government orders is coming from - Healthcare (AIIMS and State governments like Bihar looking to build hospitals), Redevelopment projects (Central Public Works Department – CPWD and NBCC – opportunity of ₹1,000-1,500 crore) and airports (modernising/increasing size of 70 airports). Opportunity in the private sector is coming from existing clients like Times of India, AMITY and Brookfield. The company is witnessing some traction in the commercial real estate sector, however the private residential side continues to witness a slowdown.
- At present, the company does not have any L1 position in orders. Slow moving orders account for ₹150 crore (vs ₹200 crore earlier).
- Order book break up based on geography - North contributed 55%, East 31% and West 14%.
- Average cost of debt is at 9.2%.
- The company has declared a dividend of ₹0.3/share in FY18. This was the first dividend declared after 6 years.
- ACIL is not looking at investing in any major capex over the next 2 years. For FY19, ACIL expects to incur a normal capex of ₹17-18 crore.
- **Update on Kota Project** – FY18 revenue stood at ₹1.25 crore. The company expects the project to break even in FY19. Additional capex of ₹8-10 crore is expected on this project. The company is open to monetize this project post achieving higher occupancy level.
- **Competitive Intensity** – ACIL continues to witness high competitive intensity. Average number of bidders for a project having a ticket size of ₹500 crore+ is 4-5 and sub ₹500 crore is 5-10. The company continues its cautious bidding approach so as to safeguard margins.

Exhibit 2: Quarterly Performance

Y/E Mar (₹ Cr.)	Q4FY17	Q1FY18	Q2FY18	Q3FY18	Q4FY18
Revenue	472	504	335	361	447
YoY Growth %	23.0	64.6	15.2	0.8	(5.3)
Raw Materials	250	275	118	146	218
% of sales	53.0	54.5	35.1	40.5	48.7
Personnel Expenses	32	32	34	34	34
% of sales	6.9	6.3	10.2	9.5	7.5
Other Expenses	146	144	133	118	142
% of sales	31.0	28.5	39.8	32.7	31.8
EBIDTA	43	54	50	62	53
EBIDTA margin %	9.1	10.6	14.9	17.3	11.9
Depreciation	6.4	6.3	6.4	6.4	6.5
Interest	7.6	3.8	4.6	12.4	4.2
Other Income	2.1	1.5	1.0	1.1	2.7
PBT	30.9	45.0	39.8	44.8	45.3
Provision for tax	10.8	15.4	14.1	15.6	14.3
Effective tax rate %	34.8	34.3	35.3	34.9	31.5
Net Profit	20.1	29.5	25.8	29.2	31.0
YoY Growth %	(24.6)	35.3	29.0	19.6	54.0
PAT margin %	4.3	5.9	7.7	8.1	6.9

Source: Company, Centrum Wealth Research

From the Technical & Derivative Desk

- The stock is moving with the territory of a 'Rising Channel' on weekly chart from last three years (see exhibit 3).
- Currently, the stock is correcting from the higher end of the mentioned channel and has also given a breakdown from 'Head & Shoulder' pattern on daily time scale.
- Also, the stock is sustaining below its '200 EMA' on daily chart, which is a negative sign for the counter.
- Since 'RSI' oscillator is rebounding from the oversold territory; a bounce back can be possible in the stock.
- But, the neckline of the 'Head & Shoulder' (which is placed around ₹368) is likely to act as a resistance. Thus, fresh buying is not advisable at current juncture.

Exhibit 3: Technical Chart

Source: Company, Centrum Wealth Research

Financials

Income Statement

Y/E Mar (₹ Cr)	FY16	FY17	FY18P	FY19E	FY20E
Revenue	1,250	1,427	1,647	1,921	2,152
<i>Growth %</i>	17.9	14.2	15.4	16.7	12.0
Raw Materials	607	726	756	957	1,072
<i>% of sales</i>	48.6	50.9	45.9	49.8	49.8
Personnel Expenses	159	154	134	171	192
<i>% of sales</i>	12.7	10.8	8.1	8.9	8.9
Other Expenses	323	374	538	536	598
<i>% of sales</i>	25.8	26.2	32.6	27.9	27.8
EBIDTA	161	173	219	257	290
EBIDTA margin %	12.9	12.1	13.3	13.4	13.5
Depreciation	20	24	26	27	28
Interest	35	27	25	7	3
Other Income	14	8	6	6	6
PBT	119	131	175	230	265
Provision for tax	35	45	59	78	90
<i>Effective tax rate %</i>	29.2	34.1	34.0	34.0	34.0
Net Profit	84	86	115	152	175
<i>Growth %</i>	31.8	1.9	34.2	31.3	15.5
PAT margin %	6.8	6.0	7.0	7.9	8.1

Source: Company, Centrum Wealth Research, P = Provisional

Balance Sheet

Y/E Mar (₹ Cr)	FY16	FY17	FY18P	FY19E	FY20E
Share capital	13	13	13	13	13
Reserves & surplus	409	495	608	744	903
Shareholder's fund	422	508	621	757	917
Loan fund	133	90	30	29	-
Total cap. employed	555	598	651	786	917
Net fixed assets	197	193	190	183	175
Deferred Tax Assets	15	13	22	22	22
Investments	6.3	6.3	-	-	-
Cash and bank	88	123	125	200	328
Inventories	205	201	189	316	342
Debtors	557	602	671	858	914
Loans & adv and OCA	89	98	47	134	151
Total current assets	939	1,023	1,033	1,508	1,734
Current lia. and prov.	602	637	594	927	1,014
Net current assets	337	386	439	582	720
Total assets	555	598	651	786	917

Source: Company, Centrum Wealth Research. OCA – Other Current Assets

Cash Flow

Y/E Mar (₹ Cr)	FY16	FY17	FY18P	FY19E	FY20E
Net Profit Before Tax	119	131	175	230	265
Depreciation	20	24	26	27	28
Others	17	16	19	0.7	(2.8)
Change in working capital	(72)	(31)	(51)	(68)	(11)
Tax expenses	(7)	(12)	(59)	(78)	(90)
Cash flow from Ops	77	127	109	112	190
Capex	(22)	(20)	(23)	(20)	(20)
Other investing activities	(3)	11	13	6	6
Cash flow from Invest	(25)	(9)	(10)	(14)	(14)
Proceeds from equity	-	-	-	-	-
Borrowings/(Repayments)	(31)	(52)	(60)	(1)	(29)
Dividend paid	-	-	(2)	(16)	(16)
Interest paid	(26)	(19)	(25)	(7)	(3)
Cash flow from financing	(58)	(71)	(88)	(23)	(48)
Net Cash Flow	(6)	48	11	74	128

Source: Company, Centrum Wealth Research

Key Ratios

Y/E Mar	FY16	FY17	FY18P	FY19E	FY20E
Return ratios (%)					
RoE	22.2	18.5	20.4	22.0	20.9
RoCE	29.5	27.3	32.0	32.9	31.5
Turnover Ratios (days)					
Inventory	54	52	43	48	56
Debtors	152	148	141	145	150
Creditors	82	83	81	83	87
Fixed asset turnover (x)	3.6	3.6	3.6	4.0	4.3
Solvency Ratio (x)					
Debt-Equity	0.3	0.2	0.0	0.0	-
Interest coverage	4.4	5.9	8.0	33.7	77.5
Per share (₹)					
EPS	12.6	12.8	17.2	22.6	26.1
BVPS	63.0	75.9	92.8	113.0	136.8
CEPS	15.6	16.4	21.1	26.7	30.3
Dividend Ratios					
DPS (₹)	-	-	0.3	2.0	2.0
Dividend Yield (%)	-	-	0.1	0.6	0.6
Dividend Payout (%)	-	-	2.0	10.3	8.9
Valuation (x)					
P/E	28.1	27.6	20.6	15.7	13.6
P/BV	5.6	4.7	3.8	3.1	2.6
EV/EBIDTA	15.0	13.5	10.4	8.6	7.0
EV/Sales	1.9	1.6	1.4	1.1	1.0

Source: Company, Centrum Wealth Research

Appendix

Disclaimer

Centrum Broking Limited ("CBL") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE), National Stock Exchange of India Ltd. (NSE) and MCX-SX Stock Exchange Limited (MCX-SX). One of our group companies, Centrum Capital Ltd is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. CBL or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of CBL. CBL and its affiliates do not make a market in the security of the company for which this report or any report was written. Further, CBL or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of CBL. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, CBL, Centrum group, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. We do not provide tax advice to our clients, and all investors are strongly advised to consult regarding any potential investment. CBL and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by CBL, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. CBL has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of CBL. This report or any portion hereof may not be printed, sold or distributed without the written consent of CBL.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither CBL nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of CBL and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

CBL and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. CBL and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by his/her, research analyst and the author of this report and/or any of his/her family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by his/her, he/she has not received any compensation from the above companies in the preceding twelve months. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavor to update the information herein on a reasonable basis, CBL, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where CBL is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Disclosures under the SEBI (Research Analysts) Regulations 2014

Disclosure of Interest Statement		
1	Business activities of Centrum Broking Limited (CBL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.
3	Registration status of CBL	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)

4	Whether Research analysts or relatives' have any financial interest in the subject company and nature of such financial interest	No
5	Whether Research analysts or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6	Whether the research analysts or his relatives has any other material conflict of interest	No
7	Whether research analysts have received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8	Whether the Research Analysts have received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No
10	Whether the Research Analysts has been engaged in market making activity of the subject company.	No

Member (and BSE)**Regn No.:**

CAPITAL MARKET SEBI REGN. NO.: BSE: INB011454239
 CAPITAL MARKET SEBI REGN. NO.: NSE: INB231454233
 DERIVATIVES SEBI REGN. NO.: NSE: INF231454233
 (TRADING & CLEARING MEMBER)
 CURRENCY DERIVATIVES: MCX-SX INE261454230
 CURRENCY DERIVATIVES:NSE (TM & SCM) – NSE 231454233

Depository Participant (DP)

CDSL DP ID: 120 – 12200
 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Website: www.centrum.co.in

Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Kavita Ravichandran
 (022) 4215 9842; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN: U67120MH1994PLC078125)

REGD. OFFICE Address Bombay Mutual Bldg., 2nd Floor, Dr. D.N. Road, Fort, Mumbai - 400 001	Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E) Mumbai 400 098. Tel: (022) 4215 9000 Fax: +91 22 4215 9344
---	--